carboplatin / Generic mfg. - LARVOL DELTA

The potential implications of dysregulated DNA damage repair genes and their modulators as adjuvants for current chemotherapy regimens in Retinoblastoma tumors. (PubMed, Mutat Res Genet Toxicol Environ Mutagen) - "Therefore, developing a more detailed perspective on the RB tumor DNA damage repair pathways is the focus of this review. Crystallizing the available information, we also propose the use of a few DDR inhibitors of the identified deregulated genes in retinoblastoma that are currently in clinical trials for other cancer types, as adjunct therapy to increase chemosensitivity of RB tumors and reduce chemotherapy-induced toxicity for better treatment outcomes."

Journal • Review • Eye Cancer • Oncology • Pediatrics • Retinal Disorders • Retinoblastoma • Solid Tumor • RB1

REVIVE: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. (clinicaltrials.gov) - P4 | N=100 | Not yet recruiting | Sponsor: AstraZeneca

Biomarker • New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status (ASH 2025) - "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) is a common regimen that is well-tolerated in older adults with other comorbidities, for whom treatment of DLBCL is challenging and has inferior outcomes...The most common 2L treatment regimens were rituximab, ifosfamide, carboplatin, plus etoposide in ASCT (n=41, 62.1%) and bendamustine plus rituximab (n=62, 18.6%) in non-ASCT treated groups...A higher percentage of patients in the non-ASCT treated group, specifically in the R-GemOx subgroup, were older with higher ECOG scores and inferior treatment related outcomes, including a minority alive at 2 years. These findings highlight a continuing unmet need for more effective, safer treatments for patients with R/R DLBCL ineligible for or unable to access ASCT or CAR-T."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma (ASH 2025) - "Introduction: Glofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) following at least one prior line of therapy, either as monotherapy or in combination with gemcitabine and oxaliplatin (GemOx)...Specifically, 6 patients (17.1%) had a history of bendamustine exposure, and 4 patients (11.4%) had undergone both autologous stem cell transplantation and chimeric antigen receptor T-cell therapy...Among them, the regimens included glofitamab monotherapy (28, 80.0%), glofitamab combination with bruton tyrosine kinase inhibitors (3, 8.6%), GemOx (2, 5.7%), polatuzumab vedotin (1, 2.9%) or dose-reduced ifosfamide, carboplatin and etoposide (1, 2.9%)... Our findings characterize disease features of heavily treated r/r aggressive B-cell lymphoma and real-world outcomes with glofitamab-based salvage. Even in the subgroups with adverse prognosis factors, glofitamab-based regimens still demonstrated..."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • CD4 • TP53

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study (ASH 2025) - "Polatuzumab vedotin (Pola), an antibody-drug conjugate targeting CD79b, has demonstrated safety and efficacy when combined with bendamustine and rituximab in transplant-ineligible patients (pts) with relapsed DLBCL pts. We evaluated the safety and efficacy of Pola-ICE regimen—comprising polatuzumab vedotin, ifosfamide, carboplatin, and etoposide—with or without the addition of rituximab in R/R DLBCL pts in the real world...All patients received Pola-ICE: Pola 1.8 mg/kg (day 1), ifosfamide 4000 mg/m² (administered in two divided doses, days 1–2, with MESNA infusion), carboplatin AUC 4 (day 2), etoposide 100 mg/m² (days 1–3), repeated every 21 days up to 6 cycles... Pola-ICE, with or without rituximab, demonstrated promising efficacy with high-quality responses and manageable toxicity in heavily pretreated R/R DLBCL pts. This salvage regimen may serve as a viable option for high-risk patients, potentially enabling subsequent curative-intent therapies."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CD79B

High transplant conversion rates with gemcitabine, dexamethasone and carboplatin (GDP)-based therapy in Relapsed/Refractory lymphoma: A real-world experience (ASH 2025) - "G-CSF and Plerixafor-mobilized peripheral blood stem cell were used in all patients...Eligible patients received agents like Rituximab, Brentuximab, and Nivolumab with additional cost per cycle...The regimen's daycare feasibility and reduced hospitalization needs offer significant quality-of-life and economic advantages. Substituting Carboplatin for Cisplatin further enhances administration convenience."

Clinical • Real-world • Real-world evidence • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • Transplantation

FDG-PET-based Selective De-escalation of Chemoradiation in Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma: a Multi-center Phase II Trial. (PubMed, Clin Cancer Res) - "FDG-PET-based RT dose personalization resulted in promising LRR outcomes in early stage oropharynx cancer with improved short- term PROs. Furthermore, HPVctDNA changes early in treatment may predict LRC."

Journal • P2 data • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial. (PubMed, Clin Cancer Res) - "This phase II trial of neoadjuvant nivolumab plus carboplatin and paclitaxel in previously untreated, locally-advanced, resectable SCCHN was well tolerated and reached its primary endpoint of pCR at the primary site. A phase III confirmatory study is warranted in advanced-stage, resectable HPV-negative SCCHN."

Journal • P2 data • Head and Neck Cancer • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Malignancy-associated internal jugular venous thrombosis following chemoradiation for oropharyngeal carcinoma (ASH 2025) - "Six months prior, he was diagnosed with HPV-positive (p16+) oropharyngeal SCC with nodal involvement, treated with carboplatin/fluorouracil chemotherapy and 14 days of radiation...Anticoagulation choice (apixaban) required careful consideration of renal function and bleeding risk (history of GI toxicity, anemia). This case underscores the heightened thrombotic risk in HNSCC patients due to the confluence of disease biology, aggressive local therapy, and patient-specific factors like CKD. Vigilance for atypical UEDVT presentations and individualized anticoagulation strategies are crucial in this complex population."

Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Head and Neck Cancer • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Oropharyngeal Cancer • Renal Disease • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thrombosis • Venous Ulcer

Trilaciclib for the prevention of chemotherapy-induced myelosuppression: A systematic review and meta-analysis (ASH 2025) - "Chemotherapy regimens were heterogeneous and included etoposide-platinum (E/P) (either cisplatin or carboplatin) (n=5), gemcitabine/carboplatin (GCb) (n=2), topotecan (n=2), FOLFOXIRI (n=1), and Carboplatin/Paclitaxel/Tislelizumab (n=1)...It also showed a positive impact on progression-free and overall survival, without compromising chemotherapy effectiveness or increasing toxicity. These findings highlight Trilaciclib's potential as a valuable adjunct to chemotherapy in appropriately selected patients."

Retrospective data • Review • Breast Cancer • Colorectal Cancer • Febrile Neutropenia • Infectious Disease • Lung Cancer • Neutropenia • Non Small Cell Lung Cancer • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia • Triple Negative Breast Cancer

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma (ASH 2025) - P1 | "With universal prior rituximab exposure in pts withR/R LBCL, salvage strategies may be improved by incorporating novel agents instead of rituximabretreatment...All pts receive at least 2 cyclesof concurrent Mosun + platinum-based chemotherapy, with chemotherapy per treating physician (Arm A:dexamethasone, cytarabine, oxaliplatin [DHAX]; Arm B: ifosfamide, carboplatin, etoposide [ICE])...Pts receive 20mg IV dexamethasone prior to each C1-C2Mosun dose, with optional steroid premeds thereafter...Nine pts experienced CRS (all gr1; no tocilizumab required)... Mosun + DHAX/ICE demonstrated a manageable safety profile with low-grade CRS.Preliminary efficacy results reveal promising anti-lymphoma activity in a high-risk population, with highCR rate and no progressions after CR with relatively short follow-up. This regimen is encouraging forfurther study. Long-term efficacy data are awaited to better assess remission durability."

Clinical • B Cell Lymphoma • Cardiovascular • CNS Disorders • CNS Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Psychiatry • Septic Shock • Thrombocytopenia • Thrombosis • CD20

Pembro-CORE: Interim analysis of a phase II PET-adapted trial omitting high-dose chemotherapy with PD-1-based salvage in first-relapsed Hodgkin lymphoma (ASH 2025) - P2 | "Moreover,severe short- and long-term side effects remain major concerns.Recent studies suggest high response rates of up to 95% and unprecedented progression-free survival(PFS) with anti-programmed cell death protein 1 (PD-1)-based salvage regimens such as pembrolizumab,gemcitabine, vinorelbine, and liposomal doxorubicin (P-GVD)...Initiatedin March 2024 at four German centers, the trial has enrolled 23 patients to date.Patients receive an initial cycle of pembrolizumab followed by two cycles of P-ICE (pembrolizumab,ifosfamide, carboplatin, etoposide). After PET restaging, complete responders continue with two morecycles of P-ICE, while patients failing to achieve a complete response switch to two cycles of P-DHAP(pembrolizumab, dexamethasone, high-dose cytarabine, cisplatin)...The interim analysis of the Pembro-CORE trial demonstrates promising early results for a PET-adapted,HD-CT-free treatment strategy in first-relapsed cHL. A high CMR of 93.3% was observed among..."

P2 data • Acute Kidney Injury • Classical Hodgkin Lymphoma • Dermatitis • Dermatology • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Nephrology • Neutropenia • Renal Disease • Respiratory Diseases

Immune checkpoint Inhibitors' impact on outcomes of relapsed and refractory Hodgkin lymphoma: A real-world study (ASH 2025) - "Adults with R/R CHL who received systemic therapy were identified and assigned to one of fivepropensity score–matched comparisons: (1) brentuximab vedotin (BV) plus nivolumab vs BV alone, (2)nivolumab alone vs BV, (3) Ifosfamide, carboplatin and etoposide (ICE) plus nivolumab vs ICE alone, (4)ICE plus pembrolizumab vs ICE alone, and (5) ICE plus nivolumab vs ICE plus pembrolizumab. Toxicity outcomes, including VTE and ICU admission, were low and comparable across treatmentarms. These findings support broader real-world adoption of ICI-based regimens and warrant prospectivevalidation."

Checkpoint inhibition • Clinical • Real-world • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Venous Thromboembolism

Quizartinib enhances conditioning for hematopoietic stem cell transplantation via transcriptional suppression of DNA repair pathways (ASH 2025) - "To assess HSC transplantation efficacy, mice were conditioned with 700 or1000 Rads of TBI, transplanted with 2 million CD45.1 bone marrow (BM) cells, and monitored for donorcell engraftment for 4 months. Quizartinib synergized with DNA damaging chemotherapeutic agents (cyclophosphamide,carboplatin, cisplatin, temozolomide, and mitoxantrone) to deplete HSPC populations. Quizartinib sensitizes HSPCs to DNA-damaging therapies via downregulation of DNA repairgenes and impaired resolution of DNA damage, resulting in enhanced HSPC depletion. This quizartinib-driven sensitization demonstrated improved engraftment after HSCT in murine models. These resultsprovide a rationale for incorporating quizartinib into reduced-intensity, myeloablative conditioningregimens to improve transplant outcomes while minimizing non-hematopoietic toxicity."

Bone Marrow Transplantation • Transplantation • BRCA1 • BRCA2 • CD34 • FLT3 • NBN • PTPRC • RAD51

Phase I/II study of zanubrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (ZR-ICE) in Relapsed/Refractory diffuse large B-cell lymphoma: Results of the Phase I portion (ASH 2025) - "The combination showed highly promising efficacy with overall response rate of 100.0% and77.8% complete response rate. These results support the ongoing phase II portion of this study."

Combination therapy • P1/2 data • B Cell Lymphoma • CNS Lymphoma • Dermatology • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Thrombocytopenia

ICE therapy for primary and secondary central nervous system involvement of lymphomas (ASH 2025) - "Due to its CNS-penetrating properties, ifosfamide, carboplatin, and etoposide (ICE) protocol with or without rituximabhas become a frequently used salvage regimen for these lymphomas...Prior methotrexate (MTX) exposure did not appearto influence treatment response. The leading cause of death was disease progression, followed by sepsisand one case of CAR-T associated ICANS.In summary, R-ICE regimen is effective and tolerable in patients with CNS involvement and can serve as abridge to advanced and potentially curative approaches. These findings support the role of R-ICE in CNSlymphoma and highlight areas for further prospective investigation."

CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma • Septic Shock

The ribosome biogenesis inhibitor CX-5461 increases platelet count in humans and enhances murine megakaryopoiesis (ASH 2025) - "CX-5461 treatment reduced the depth of carboplatin-induced thrombocytopenia and accelerated platelet recovery. RNA-Polymerase I inhibition offer a novel target for treating thrombocytopenia and a tool tofurther our understanding of thrombopoiesis. This unique property distinguishes CX-5461, and otherinhibitors of RNA Pol I transcription from other anticancer agents and highlights this class of reagent tohave potential dual utility as both antineoplastic and thrombopoietic agents, particularly in settings ofchemotherapy-induced thrombocytopenia or in patients with impaired TPO signalling."

Preclinical • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Thrombocytopenia

Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL) (ASH 2025) - "Among 481 patients who initiated 2L from 2018-21 (before 2L CAR T was approved), the largest subset(38.3%, n=184) received rituximab in combination with ifosfamide, carboplatin, etoposide (R-ICE) ordexamethasone, ara-C, and cisplatin (R-DHAP), of whom 20.7% (38/184) subsequently received HSCT.Among 365 patients who initiated 2L from 2022-24, only 41 (11.2%) received R-ICE/DHAP, of whom 7.3%(3/41) subsequently received HSCT. With the emergence of alternative 2L therapies like CAR T, the paradigm of 2L R-ICE/DHAP followed byHSCT may be losing relevance. CAR T therapy is extending treatment-free intervals, a proxy for prolongeddisease control, and is showing promise in extending rwOS over less durable alternatives. These findingsalso reinforce the value of CAR T in improving survival outcomes in 2L and 3L settings and the potentialimpact of bringing CAR T into an upfront setting."

Clinical • HEOR • Real-world • Real-world evidence • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis (ASH 2025) - "We hypothesized that by protecting HSPCs from the cytotoxic effects of chemotherapy,trilaciclib might also reduce the clonal expansion of TP53-mutant CH during chemotherapy.We obtained serial blood samples from healthy controls (n=176) and three placebo-controlledrandomized clinical trials of trilaciclib including patients with (1) SCLC (n=65) receiving carboplatin andetoposide, (2) metastatic colorectal cancer (mCRC) (n=125) receivingleucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) plus bevacizumab, and (3) metastatic triplenegative breast cancer (mTNBC) (n=34) receiving gemcitabine and carboplatin...Similar effectswere seen with the oral CDK4/6 inhibitor palbociclib and using a dominant negative form of CDK6introduced into p53 mutant HSPCs.Single cell RNA-seq of chimeric mice treated with carboplatin with trilaciclib or single agent controlsrevealed that CDK4/6 inhibition treatment promotes HSC and myeloid progenitor quiescence whilemitigating the myeloid..."

Breast Cancer • Colorectal Cancer • Eye Cancer • Hematological Malignancies • Lung Cancer • Retinal Disorders • Retinoblastoma • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer • PTPRC • TP53

Adding selinexor to ifosfamide, etoposide and desametasone does not improve the outcome in relapsed and refractory peripheral T-cell lymphomas: First report of phase II S-ide study. (ASH 2025) - P2 | "Introduction: The prognosis of relapsed or refractory (R/R) Peripheral T-cell lymphomas (PTCL) is verypoor, except for CD30+ ALK positive PTCLs patients treated with brentuximab-vedotin andchemotherapy...In a small phase I study, selinexor incombination with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (D-ICE) has shownpromising overall response rate (ORR, 91%) and complete response (CR, 82%) in R/R PTCLs, (Tang et al.Haematologica 2021)... In the pilot phase II study S-IDE, the primary end-point was not met, with ORR of 41% at theend of induction. The addition of selinexor to ifosfamide, etoposide, dexamethasone did not ameliorateprognosis in relapsed/refractory PTCLs, the clinical outcome is similar to standard therapies available inthis setting. Biological analyses are ongoing."

P2 data • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Respiratory Diseases • T Cell Non-Hodgkin Lymphoma • ALK • CDKN2A • CDKN2B • FAT1 • GATA3 • KDM6A • KMT2A • KMT2B • PRDM1 • STAT3 • TBX21 • TNFRSF8 • TP53 • TP63 • XPO1

Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct Pro-inflammatory tmes (ASH 2025) - P1 | "Experiments investigating activity of IL-7/IL-15-iMSCs in carboplatin-resistant ID8models are ongoing and will be reported... We demonstrate that IL-7/IL-15-iMSCs display potent in vitro immunostimulatory activity,inducing robust T cell proliferation and activation. IL-7/IL-15-secreting iMSCs convert animmunosuppressive TME into a "hot" milieu, defined by massive T-cell and macrophage infiltration, M1polarization, and restoration of T-cell functionality. Gene-modified iMSC-induced reprogramming ofovarian TME resulted in reduced tumor burden and improved survival in a murine ovarian cancer model.Results support the potential of IL-7/IL-15-iMSCs as a novel immunotherapeutic platform for overcomingimmune resistance in cancer, including hematological malignancies."

Biomarker • IO biomarker • Tumor microenvironment • Breast Cancer • Hematological Malignancies • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • Triple Negative Breast Cancer • BCL2 • CD163 • IFNB1 • IL15 • IL7 • PD-L1

Diagnosis and Treatment of Laryngeal Extranodal Natural Killer/T-cell Lymphoma. (PubMed, Cureus) - "The patient received CHOP chemotherapy (cyclophosphamide 700 mg, doxorubicin 50 mg, vincristine 2 mg, dexamethasone 20 mg), which was later changed to DeVIC (dexamethasone 40 mg, etoposide 70 mg, ifosfamide 1,000 mg, carboplatin 200 mg) with local radiotherapy. Due to the inability to place a nasogastric tube, a Witzel gastrostomy was performed. However, the patient died from non-oncological causes."

Journal • Cough • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Laryngeal Cancer • Lymphoma • Natural Killer/T-cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Squamous Cell Carcinoma • T Cell Non-Hodgkin Lymphoma • Tuberculosis

A prospective randomized, double-blind controlled trial of olanzapine versus placebo in addition to ondansetron plus dexamethasone as antiemetic prophylaxis in patients receiving moderately emetogenic chemotherapy (ESMO Asia 2025) - "Given the comparable efficacy of olanzapine, this study evaluated the effectiveness of 5 mg olanzapine (OLN) in combination with ondansetron and dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing MEC. This double-blind, randomized controlled trial included patients receiving their first cycle of oxaliplatin-, carboplatin-, or irinotecan-based chemotherapy. Olanzapine (5 mg) combined with ondansetron and dexamethasone significantly improved prevention of CINV in patients receiving MEC. This regimen may serve as a new standard of care."

Clinical • Chemotherapy-Induced Nausea and Vomiting • Oncology

Crizotinib plus chemotherapy versus crizotinib alone in advanced non-small cell lung cancer with ALK rearrangement (ESMO Asia 2025) - "Background: Lorlatinib, a 3rd-gen ALK inhibitor (ALKi), & 2nd-gen ALK inhibitors are recommended for the treatment of advanced ALK-rearranged NSCLC...Participants were randomized 1:1 to receive Crizotinib 250 mg BD or Crizotinib 250 mg BD + Pemetrexed 500mg/m2 + Carboplatin AUC 5 q3w; followed by Crizotinib + Pemetrexed... The combination of crizotinib + chemotherapy did not improve the DCR and PFS in patients with ALK re-arranged NSCLC."

Late-breaking abstract • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Thoracic Cancer • ALK

TOURMALINE study of durvalumab (D) in combination with gemcitabine (G)-based chemotherapy in advanced biliary tract cancer (aBTC): early safety and efficacy results in participants (pts) from Asia (ESMO Asia 2025) - P3 | "We report early safety and efficacy data within a subgroup of pts from Asia. Pts receive D 1500 mg (first infusion: 60 min; subsequent infusions: 30 min) with an investigator-selected G-based chemotherapy (D + G alone or in combination with oxaliplatin [O], carboplatin [C], cisplatin [cis], tegafur-gimeracil-oteracil [S-1], cis + S-1, or cis + nab-paclitaxel [P]). In pts from Asia, the safety profiles of all study tx were manageable. Safety results for pts from Asia were comparable to the global TOURMALINE population and TOPAZ-1 study. Interim ORR is promising."

Clinical • Combination therapy • Metastases • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor